Vildagliptin has established itself over the years by controlling the blood sugar levels in patients with type 2 diabetes mellitus. It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It also displays significant HbA1c lowering and has a low risk of edema, as well as that of hypoglycemia. These characteristic features make vildagliptin a favorable partner for combination therapy as well as newer formulations like sustained release.
In this video, Prof. Dr Aravinda Jagadeesha, a diabetologist and the chairman at Dr. Aravinds Diabetes Centre in Bengaluru, India talks about how Vildagliptin and how it has proven itself in the past 15 years. In particular, Dr Jagadeesha provides his viewpoints on the cardiac safety profile of Vildagliptin 100mg SR.
In the case of Cardiovascular Safety, Vildagliptin has a plethora of studies including 3 Real-world studies, 3 Meta-analyses, and 1 RCT, establishing safety in over 10 lakh patients. The studies demonstrated that Vildagliptin is not associated with increased Cardiovascular risk, including the risk of Chronic Heart Failure. Even a thorough QT study demonstrated that Vildagliptin has no prolonged QT interval or effect on cardiac conduction even at the highest daily therapeutic dose.